Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
0013-7227/02/$15.00/0 Printed in U.S.A. The Journal of Clinical Endocrinology & Metabolism 87(10):4462– 4469 Copyright © 2002 by The Endocrine Society doi: 10.1210/jc.2002-020750 Large Differences in Incidences of Overt Hyper- and Hypothyroidism Associated with a Small Difference in Iodine Intake: A Prospective Comparative RegisterBased Population Survey INGE BÜLOW PEDERSEN, NILS KNUDSEN, TORBEN JØRGENSEN, HANS PERRILD, LARS OVESEN, AND PETER LAURBERG Department of Endocrinology and Medicine (I.B.P., P.L.), Aalborg Hospital, DK-9000 Aalborg, Denmark; Endocrine Unit, Department of Internal Medicine I (N.K., H.P.), Bispebjerg University Hospital, DK-2400 Copenhagen, Denmark; Centre for Preventive Medicine (N.K., T.J.), Glostrup Hospital, DK-2600 Glostrup, Denmark; and Institute of Food Research and Nutrition (L.O.), the Danish Food Administration, DK-2860 Soeborg, Denmark Around 3– 4 billion people in the world are covered by iodine supplementation programs to prevent developmental brain damage and other iodine deficiency (ID) disorders. Mild ID is associated with more hyperthyroidism and less hypothyroidism in the population than a high iodine intake. Knowledge of the iodine intake levels where the shifts in incidences occur is important for planning of iodine supplementation programs. A computer-based register linked to thyroid diagnostic laboratories was used to continuously identify all new cases of overt hyper- and hypothyroidism in two population cohorts with moderate and mild ID, respectively (Aalborg, n ⴝ 310,124; urinary iodine, 45 g/liter; and Copenhagen, n ⴝ 225,707; urinary iodine, 61 g/liter). The investigation was initiated before iodization of salt in Denmark and was part of the monitoring program. In 1997–1998, the incidence rate of overt hyperthyroidism was high in the area with the lowest iodine intake (92.9/100,000 per year) compared with the area with only mild ID (65.4/ P OPULATIONS WITH A LOW iodine intake from natural sources are found in all continents and most countries (1). When iodine deficiency (ID) is severe, thyroid hormone synthesis may be insufficient, and there is a high risk of fetal and neonatal hypothyroidism with increased mortality, developmental brain damage, and a range of other abnormalities (2, 3). Iodine supplementation governed by national health care agencies and guided by international organizations (International Council for the Control of Iodine Deficiency Disorders, World Health Organization, and United Nations Children’s Fund) has successfully reduced the risk of ID disorders in most countries, with programs now covering on the order of 3– 4 billion people in the world (4). If the iodine supply to the thyroid is only moderately low, the gland may compensate by a number of mechanisms to maintain sufficient thyroid hormone production (5). Somehow, the compensating mechanisms may, over years, trigger development of multifocal autonomous growth and function Abbreviations: CI, 95% Confidence interval(s); FT4, free T4; GP, general practitioner; ID, iodine deficiency; SRR, standardized rate ratio; TT4, total T4. 100,000 per year). Standardized rate ratio was 1.49, and 95% confidence interval was 1.22–1.81. The opposite relationship was present for overt hypothyroidism (moderate ID, 26.5/ 100,000 per year; mild ID, 40.1/100,000 per year; standardized rate ratio, 0.73; 95% confidence interval, 0.55– 0.97). The different incidence rates were confirmed during each of the two following years. The results of this prospective investigation of the incidence of overt hyper- and hypothyroidism suggest that iodine supplementation of a population may increase the incidence of overt hypothyroidism, even if the population is moderately iodine-deficient. In such a population, the increase in risk of hypothyroidism should be weighed against the risk of ID disorders such as hyperthyroidism due to multinodular toxic goiter. The optimal level of iodine intake to prevent thyroid disease may be a relatively narrow range around the recommended daily iodine intake of 150 g. (J Clin Endocrinol Metab 87: 4462– 4469, 2002) of the thyroid gland with scattered cell clones harboring activating mutations of the TSH receptor (6, 7). As a consequence, mild and moderate ID is associated with a high incidence and prevalence of goiter and nodular hyperthyroidism in middle-aged and elderly subjects (8, 9). A very high iodine intake may, however, also lead to disease (10). Goiter and elevated serum TSH, indicating impaired thyroid function, are common in children and adults with a high iodine intake (11–13). This may be due to inappropriate autoregulation of the thyroid by iodine. Excess iodine inhibits the activity of several thyroidal processes, possibly via synthesis of iodine containing arachidonic acid derivatives (5). Moreover, iodine may enhance thyroid autoimmunity, leading to hypofunction of the gland (14 –17). Hence, both low and high iodine intake of a population are associated with an increase in the risk of thyroid disease, albeit the consequences are more severe in ID than in iodine excess (10, 18). It is important for planning of public iodine supplementation programs to know at which level of iodine intake the shift from a high incidence of nodular hyperthyroidism to a high incidence of thyroid hypofunction takes place. 4462 12.6– 40.4 41.7– 83.9 52.5–101.3 100.5–167.1 144.3–239.9 197.7–322.3 316.1–532.7 83.0–102.8 0.2– 8.8 3.3–16.7 0–5.6 9.7–34.7 0–28.5 16.0– 48.8 25.3–73.9 68.4–148.8 49.9–153.5 21.2–31.8 2.2 4.9 1.9 22.2 14.2 32.4 49.6 108.6 100.7 26.5 Hypo Hypo Hyper 95% CId 0 0 26.5 62.8 76.9 133.8 192.1 260.0 424.4 92.9 a 0 0 3.6 21.5 31.9 38.7 96.6 132.9 225.5 36.0 0 0 0 1 0 2 1 2 3 9 0 1 3 3 12 15 26 24 13 97 1 2 1 13 7 17 17 30 17 105 39,321 (48.7/51.3) 35,311 (48.7/51.3) 45,362 (47.7/52.3) 46,375 (48.4/51.6) 42,375 (49.3/50.7) 39,715 (49.8/50.2) 27,659 (51.9/48.1) 22,090 (56.2/43.8) 11,916 (64.9/35.1) 310,124 (50.2/49.8) 0 –9 10 –19 20 –29 30 –39 40 – 49 50 –59 60 – 69 70 –79 ⬎80 All ages 0 1 17 37 50 77 88 91 72 433 Hyper Hypo Hyper Hypo Hyper Results from the 14 months of observation in Aalborg (March 1, 1997, to April 30, 1998). F, Female; M, male. Number of cases from database and contact to GP. b Number of cases excluded during final evaluation. c Incidence rate: number of new cases/100,000 per year. d 95% CI of the total incidences of hyper- and hypothyroidism. 4.5 10.0 4.0 42.0 28.7 56.4 71.7 145.0 121.9 43.5 0 0 51.5 107.0 123.1 229.9 280.8 359.0 532.0 149.1 0 0 0 3.6 0 8.6 25.8 62.0 61.5 9.4 Hypo Hyper Hypo Hyper Total Female Male Study population Total (F/M %) Details of the register and the methodological evaluations performed have been published recently (25). In brief, all blood tests from subjects living in the two study areas were analyzed in one of four clinical chemistry laboratories (one in Aalborg, three in Copenhagen). Results of TSH and thyroid hormone measurements were continuously imported from the laboratory databases into a register database, which automatically identified overt hyperthyroidism (low serum TSH combined with a high serum T3 and/or serum T4), and overt hypothyroidism (high serum TSH combined with a low serum T4). A list of not previously registered cases of biochemical hyper- and hypothyroidism was generated each day and evaluated by: 1) searching in laboratory databases and diagnosis registers of the hospitals in the area, 2) rechecking that the patient lived in one of the two geographical areas, and 3) contacting the patients’ general practitioner (GP) for verification. All new cases were subsequently invited to an interview and physical examination with blood sampling for a final evaluation. Before the registration was initiated, various details of the methodology were evaluated (25). This included evaluation of the diagnostic performance of the participating laboratories. A reference panel of normal sera (n ⫽ 100) was analyzed in the four laboratories. No systematic differences in distribution of values with reference ranges were found. The database identification of new cases was tested by a 60-d run in Age (yr) Identification of new cases of hyper- and hypothyroidism Incidence ratec The present study is part of The Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr), which comprises a number of register studies and a cohort study. DanThyr is the official clinical monitoring of the Danish iodine supplementation program, and it is projected to run for 9 yr in its present form. The present register study measured prospectively the incidence rates of hyper- and hypothyroidism in two population cohorts with mild and moderate ID before iodine supplementation. Two open population cohorts representing the geographical variation in iodine intake in Denmark (19) were selected for monitoring. One population cohort consisted of 310,124 subjects living in the city of Aalborg and the surrounding municipalities in Northern Jutland. This area had moderate ID with a median iodine concentration in urine of 45 g/liter (estimated iodine excretion, 62 g/24 h) in subjects taking no supplements. The other population cohort comprised 225,707 subjects living in the geographical area around Bispebjerg and Frederiksberg Hospital in Copenhagen. The area had mild ID with a median urinary iodine concentration of 61 g/liter (estimated iodine excretion, 93 g/24 h) when no supplements were taken. Median urinary iodine values were moderately higher if all subjects were included (Aalborg, 53 g/liter; Copenhagen, 68 g/liter). The iodine excretion values were obtained in a simultaneous cohort study of 4649 subjects from the two areas (21, 22). The participants had been randomly selected in certain age and sex groups from the general population (females aged 18 –22, 25–30, 40 – 45, and 60 – 65 yr; and males aged 60 – 65 yr). In all groups, the urinary iodine excretion was higher in Copenhagen than in Aalborg (21). Age and sex compositions of the present population cohorts at January 1, 1998, are given in Tables 1 and 2. Information on the size and composition of population cohorts on January 1, 1998, 1999, and 2000 was obtained from the Danish Bureau of Statistics. The Danish population is relatively homogeneous, and the population iodine intake has been rather stable over at least 30 – 40 yr, with the exception of a subgroup now taking vitamin mineral tablets containing iodine (23, 24). Excluded during verificationb Subjects and Methods Population cohorts New cases from databasea In this prospective study, we compared the long-term effects of different grades of low iodine intake on the incidence of overt thyroid function abnormalities in two population cohorts with different iodine intake levels (moderate and mild ID) (19) due to differences in water iodine contents in the two localities (20). The results suggest that any increase in iodine intake of a population that is not severely iodine deficient may induce an increase in the incidence of hypothyroidism. J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 4463 TABLE 1. Total number and incidence rates of hyper- and hypothyroidism according to age and sex groups in an open population cohort from Aalborg with moderate ID Pedersen et al. • Thyroid Disease and Iodine Intake 1.2–17.4 0.2–18.4 4.3–39.1 17.6– 68.4 57.9–152.5 44.6–125.6 152.5–303.5 32.2– 48.0 8.3–32.5 22.5–19.3 52.1–121.7 31.9–93.3 79.7–186.1 117.1–233.3 136.2–280.6 55.3–75.5 0–12.3 3.9 0 9.3 9.3 21.7 43.0 105.2 85.1 228.0 40.1 Evaluation of cases a 0 0 3 2 2 1 5 8 4 25 1 0 1 7 5 3 4 11 9 41 1 0 12 25 29 19 28 46 41 201 0 –9 10 –19 20 –29 30 –39 40 – 49 50 –59 60 – 69 70 –79 ⬎80 All ages 23,447 (48.7/51.3) 14,397 (49.7/50.3) 49,756 (52.4/47.6) 39,721 (46.5/53.5) 25,502 (48.3/51.7) 23,605 (50.2/49.8) 16,674 (55.5/44.5) 18,433 (64.0/36.0) 14,172 (74.1/25.9) 225,707 (52.7/47.3) 1 0 8 6 8 12 24 25 39 123 Hypo Hyper Hypo Hyper Study population Total (F/M %) Age (yr) Results from the 13 months of observation in Copenhagen (May 1, 1997, to May 31, 1998). F, Female; M, male. Number of cases from database and contact to GP. b Number of cases excluded during final evaluation. c Incidence rate: number of new cases/100,000 per year. d 95% CI of the total incidences of hyper- and hypothyroidism. 0 0 20.4 41.8 86.9 62.6 132.9 175.2 208.4 65.4 0 0 17.7 15.0 29.9 85.7 169.5 86.1 237.4 60.6 7.7 0 0 4.3 14.0 0 24.9 83.4 201.1 17.3 0 0 3.9 13.0 56.1 15.7 49.8 152.9 50.3 26.8 0 0 35.4 74.9 119.8 109.0 199.4 187.9 263.8 101.7 Hyper Hypo Hyper Hypo Hyper Female Male Incidence ratec Excluded during verificationb New cases from databasea Pedersen et al. • Thyroid Disease and Iodine Intake Aalborg with parallel manual and computer-based evaluation of all abnormal TSH results (n ⫽ 2159). The results obtained were identical. Furthermore, we evaluated the risk to be lost from detection because of GPs outside the study area. This was found to be negligible. Finally, the use of TSH as the primary test in the diagnostic algorithm was evaluated. No cases of thyroid dysfunction had been diagnosed based on T3 and T4 alone. Total Hypo Hyper 95% CId Hypo J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 TABLE 2. Total number and incidence rates of hyper- and hypothyroidism according to age and sex groups in an open population cohort from Copenhagen with mild ID 4464 In two of the laboratories in Copenhagen, serum free T4 (FT4) was analyzed in addition to serum total T4 (TT4). The other laboratories relied on supplementary measurements of serum thyroid binding globulin or a T3 test to evaluate abnormalities of protein binding of T4 and T3 in serum. Because this was a comparative study, cases registered on condition of an abnormal FT4 combined with a normal TT4 were excluded to avoid bias [cases with low TSH combined with normal TT3 and TT4 but high FT4 (n ⫽ 7) or high TSH combined with normal TT4 but low FT4 (n ⫽ 16)]. Cases with abnormal FT4 and missing TT4 (n ⫽ 6) were included. During the final evaluation, another 149 apparently new cases were excluded for the following reasons: normalization of thyroid hormones (serum T4 and T3) within 3 wk without treatment or clinical signs of acute or subacute thyroiditis (n ⫽ 105); abnormal protein binding of thyroid hormones (n ⫽ 3); amiodarone treatment with low TSH and high TT4 but normal TT3 (n ⫽ 16); cases primarily verified by GP to be new, despite earlier treatment for thyroid disease (n ⫽ 14); treatment with levo-T4 for a psychiatric disorder (n ⫽ 4); substitution with levo-T4 after thyroid surgery (n ⫽ 3); overtreatment of subclinical hyperthyroidism with carbimazole (n ⫽ 1); and laboratory errors (n ⫽ 3). Such detailed evaluation with new blood tests and clinical follow-up was performed in 94.4% of the patients in Aalborg and 88.5% in Copenhagen. Information on cases excluded during evaluation is given in Tables 1 and 2. From the persons evaluated in this way, we calculated for each population cohort the additional fraction and number of patients with biochemical hyper- and hypothyroidism that hypothetically would have been excluded in each sex and age group, if follow-up had been performed in all patients. Adjustment of incidence values using these data did not alter the values substantially, and no difference in statistical results occurred. Registration after introduction of iodized salt The incidence rates of hyper- and hypothyroidism in the study period and during the two subsequent 1-yr periods after introduction of iodine supplementation were compared. The incidence rates were calculated from the number of new cases identified by the register database and verified by contact to GPs, but without follow-up evaluation of patients. Laboratory activity The register accumulated information on the number of thyroid laboratory tests in the two population cohorts performed as part of diagnosis and control of thyroid disorders. Overall, the activity was similar in the two areas and moderately increasing during the time period studied. The number of TSH analyses was slightly higher in Copenhagen, whereas more T4 and T3 analyses were performed in Aalborg (Table 3). TSH, T3 and T4 analyses used Aalborg Hospital Laboratory. TSH, immunoluminometric assay (Lumitest, Brahms Diagnostica, Berlin, Germany); reference interval, 0.3– 4.5 mU/ liter. T3 and T4, competitive RIA (Amerlex-m T3 and T4 RIA Kit, OrthoClinical Diagnostics, Raritan, NJ); reference T3, 1.2–2.7 nmol/liter; T4, 60 –140 nmol/liter. Frederiksberg Hospital Laboratory. TSH, time-resolved fluoroimmunometric assay based on direct sandwich technique (AutoDelfia hTSH Ultra kit, Wallac, Inc., Gaithersburg, MD); reference, 0.15– 4.5 mU/liter. T3 and T4, time-resolved fluoroimmunoassay based on competitive reaction (AutoDelfia T3 and T4 kit, Wallac, Inc.); reference T3, 0.9 –2.7 nmol/liter; T4, 60 –160 nmol/liter. Pedersen et al. • Thyroid Disease and Iodine Intake J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 4465 TABLE 3. Thyroid laboratory tests per 100,000 inhabitants per year in the open cohorts from Aalborg (moderate ID) and Copenhagen (mild ID) before and the first 2 yr after iodized salt was introduced Aalborg Serum Serum Serum Serum TSH T3 T4 FT4b Copenhagen Before 1st yr aftera 2nd yr aftera Before 1st yr aftera 2nd yr aftera 19,368 9,654 11,340 0 21,245 11,072 11,618 0 23,051 12,502 13,006 0 22,345 7,576 7,630 2,714 23,624 7,538 7,578 2,823 24,408 7,500 7,548 3,012 Number of tests per 100,000 inhabitants per year performed by the laboratories in the two cohort areas. Period in relation to iodization of salt. Before: Aalborg, March 1, 1997, to April 30, 1998; Copenhagen, May 1, 1997, to May 31, 1998. 1st yr after: June 1, 1998, to May 31, 1999. 2nd yr after: June 1, 1999, to May 31, 2000. b Many Danish laboratories are not using measurements of FT4 and FT3 in serum for routine purposes due to the insufficient methodology of most commercial methods. In this study, FT4 was only measured in two of the laboratories in Copenhagen. a FIG. 1. The incidence rates of hyper- and hypothyroidism in males and females in two open population cohorts with different levels of iodine intake (Aalborg (f) with moderate ID, and Copenhagen (䡺) with mild ID). The incidence rates were calculated after follow-up evaluation of patients. Both hyper- and hypothyroidism (age standardized) were more common in females than in males in both cohorts [hyperthyroidism, Aalborg, SRR (females/males), 3.24; CI, 2.36 – 4.44; Copenhagen, SRR, 3.02; CI, 1.99 – 4.56; and hypothyroidism, Aalborg, SRR (females/males), 3.18; CI, 1.75–5.78; Copenhagen, SRR, 1.97; CI, 1.17–3.30]. The incidence rate of hyperthyroidism was higher in Aalborg than in Copenhagen [SRR (Aalborg/Copenhagen) total, 1.49; CI, 1.22–1.81; females, SRR, 1.65; CI, 1.34 –2.04; males, SRR, 1.54; CI, 0.96 –2.46]. The incidence rate of hypothyroidism was higher in Copenhagen than in Aalborg [SRR (Aalborg/Copenhagen) total, 0.73; CI, 0.55– 0.97; females, SRR, 0.79; CI, 0.57–1.09; males, SRR, 0.49; CI, 0.24 –1.0]. Bispebjerg Hospital Laboratory. TSH, microparticle enzyme immunoassay (Axsym ultrasensitive hTSH II, Abbott Laboratories, Abbott Park, IL); reference, 0.15–5.0 mU/liter. T3, microparticle enzyme immunoassay (Axsym T3, Abbott Laboratories); reference, 1.2–2.3 nmol/liter. T4, fluorescence polarization immunoassay (Axsym, Abbott Laboratories); reference, 60 –140 nmol/liter. FT4, microparticle enzyme immunoassay (Axsym FT4, Abbott Laboratories); reference, 9.0 –24.0 pmol/liter. The Laboratory of General Practitioners in Copenhagen. TSH, two-sided chemiluminometric immunoassay (Ciba Corning ACS TSH, Ciba Corning Diagnostic, Medfield, MA); reference, 0.2–5.0 mU/liter. T3, T4, and FT4, competetive immunoassay (Ciba Corning ACS T3, ACS T4, and ACS FT4, all by Ciba Corning Diagnostic); reference T3, 1.1–2.6 nmol/liter; T4, 60 –140 nmol/liter; and FT4, 10.0 –22.0 pmol/liter. All involved TSH assays had a functional sensitivity below 0.07 mU/liter. Statistical methods The 95% confidence intervals (CI) for standardized rate ratios (SRRs) were calculated after log transformation of the respective rates (26). When comparing the total incidence rates, the analyses were performed after age and sex standardizing of the Aalborg cohort to the Copenhagen cohort. Female and male incidence rates were compared after age standardizing to the Copenhagen females (Fig. 1). Standardization to a female-to-male ratio of 1:1 was performed when comparing incidence rates between different age groups (Fig. 2). The calculations were based on an assumption of Poisson distribution of cases. Level of significance was set to 5%. The cumulative risk was calculated by a summation of the agespecific incidence rates multiplied by 10, because the risk for each year within the 10-yr age group was assumed to be constant. No correction for prevalent cases was attempted. 4466 J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 Pedersen et al. • Thyroid Disease and Iodine Intake FIG. 2. The incidence rates of hyper- and hypothyroidism in different age groups in Aalborg (f) with moderate ID and Copenhagen (䡺) with mild ID. In both cohorts, the sex standardized incidence rates of hyper- and hypothyroidism increased (data not shown). Differences in incidence rates between the Aalborg and Copenhagen cohorts were statistically significant in the age group above 60 yr [hyperthyroidism, SRR (Aalborg/Copenhagen), 1.62; CI, 1.26 –2.09; and hypothyroidism, SRR, 0.63; CI, 0.44 – 0.89]. In the other age groups, only nonsignificant tendencies were observed (data not shown). The study was approved by the regional Ethics Committees in Northern Jutland and Copenhagen. Results The primary investigation took place in 1997–98 and lasted 14 months in Aalborg and 13 months in Copenhagen, until iodized salt was introduced in June 1998. Subsequently, data from the first 2 yr after iodization of salt were included. Details on the number of new patients are given in Tables 1 and 2. The crude incidence rate of overt hyperthyroidism (with no correction for age and sex distribution) was high in Aalborg (92.9/100,000 per year) compared with Copenhagen (65.4/100,000 per year). On the other hand, overt hypothyroidism was more common in Copenhagen (40.1/100,000 per year) than in Aalborg (26.5/100,000 per year). There were small differences in the age composition of the two population cohorts (Tables 1 and 2). Age and sex standardization of the Aalborg cohort to the Copenhagen cohort affected the incidence rates little, and differences between cohorts were statistically significant (hyperthyroidism, SRR (Aalborg/ Copenhagen), 1.49; CI, 1.22–1.81; hypothyroidism, SRR, 0.73; CI, 0.55– 0.97). In both areas, hyper- and hypothyroidism were more common in females than in males (Fig. 1), and the incidence rates of both hyper- and hypothyroidism increased with age (Fig. 2). The pattern of difference between the population cohorts TABLE 4. Cumulative risk (%) of having diagnosed thyroid dysfunction before age 90 yr in Aalborg with moderate ID and Copenhagen with mild ID Hyperthyroidism Hypothyroidism Hyper- or hypothyroidism Aalborg (F/M) Copenhagen (F/M) 11.8 (16.8/5.5) 3.4 (4.8/1.6) 15.2 (21.6/7.1) 7.3 (9.9/3.4) 5.1 (6.4/3.4) 12.4 (16.3/6.8) Cumulative risk was calculated up to 90 yr of age from the incidence rates given in Tables 1 and 2. F, Female; M, male. was the same in nearly all subgroups; hyperthyroidism was more frequent in the cohort with moderate ID, whereas hypothyroidism was more frequent in the cohort with mild ID. The cumulative risk of having diagnosed thyroid dysfunction up to the age of 90 yr is shown in Table 4. The highest risk (21.7%) was found in females from Aalborg. Figure 3 depicts the incidence rates of hyper- and hypothyroidism in the primary study period and during the two subsequent 1-yr periods. The incidence rates given were calculated from the number of new cases identified by the register database and verified by contact to GPs, but without follow-up evaluation of patients. The differences in incidence rates of hyper- and hypothyroidism between population cohorts persisted in the 2 yr of follow-up. Over the entire study period, the incidence rate of thyroid dysfunction (hyper- plus hypothyroidism) was 163.8/100,000 per year in Aalborg and Pedersen et al. • Thyroid Disease and Iodine Intake J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 4467 FIG. 3. The incidence rates of hyper- and hypothyroidism in the two open population cohorts with moderate ID (Aalborg) and mild ID (Copenhagen) before and after iodized salt was introduced in Denmark by June 1998. The rates were calculated from the number of new cases identified by the register database and verified by contact with GPs, but without follow-up evaluation of patients. The differences in incidence rates of hyper- and hypothyroidism between the two cohorts were significant in all three periods. Hyperthyroidism: before salt iodization, SRR (Aalborg/Copenhagen), 1.62; CI, 1.37–1.93; first year after, SRR, 1.79; CI, 1.52–2.12; second year after, SRR, 1.94, CI, 1.64 –2.30. Hypothyroidism: before salt iodization, SRR (Aalborg/Copenhagen), 0.66; CI, 0.51– 0.87; first year after, SRR, 0.65; CI, 0.49 – 0.85; second year after, SRR, 0.65; CI, 0.49 – 0.85. During the 2 yr after salt iodization, the use of iodized salt and the increase in iodine intake was low (on average, ⬍5 g/d). Compulsory iodization has now been introduced. 133.4/100,000 per year in Copenhagen (SRR, 1.35; CI, 1.25–1.47). In the Aalborg population cohort, an increase in incidence rate of hyperthyroidism was seen in the second year after iodine supplementation (SSR before vs. second year after supplementation, 0.74; CI, 0.68 – 0.81). No significant alterations were seen in incidence rates of hyperthyroidism in Copenhagen or in hypothyroidism in either population cohort. Discussion This prospective comparative epidemiological study showed that the incidence rate of overt hyperthyroidism was much higher in a population cohort with moderate ID than in an otherwise comparable cohort with mild ID. The opposite relationship was present for overt hypothyroidism, where the highest incidence rate was found in the area with mild ID. Before the recent implementation of widespread iodine supplementation, ID was the most common cause of preventable brain damage in the world (2, 3), and public iodine supplementation programs are thus important parts of global health care. In areas less severely affected, such as Denmark, a low iodine intake predominantly manifests with a high risk of goiter and autonomous thyroid nodules with hyperthyroidism (27). The primary purpose of iodine supplementation in such areas is to prevent goiter and nodular hyperthyroidism. The present study indicates that considerable prevention can be expected already at a relatively low level of iodine supplementation. This is supported by our previous findings in a comparative cohort study (n ⫽ 4649) from the same two areas with moderate and mild ID. The prevalence of goiter was considerably higher in the area with moderate ID (22). Moreover, in moderate ID we observed a gradual decrease in median serum TSH with age, as a sign of development of autonomous thyroid nodules. In mild ID, this was much less prominent (28). The effect of iodine on the thyroid gland is complex, with a U-shaped relation between iodine intake and risk of thyroid disease, because both low and high iodine intake are associated with an increased risk (3, 10, 18). When iodine intake is high, the prevalence of hypothyroidism and diffuse thyroid enlargement is high compared with populations with iodine intake around the recommended level of 150 g/d (11). The mechanism behind this impairment of thyroid function is unknown, but both iodine enhancement of thyroid autoimmunity and reversible iodine inhibition of thyroid function in susceptible subjects are possibly involved (5, 14 –17). There is only limited knowledge of the threshold of iodine intake, above which the increase in hypothyroidism begins. In the present study, we found a high incidence rate of hypothyroidism in Copenhagen with mild ID compared with Aalborg with moderate ID. This suggests that the increase in hypothyroidism, induced by an increase in iodine intake, may start already at low levels of iodine intake. The increase in hypothyroidism may continue over a wide range of iodine intake levels because it was observed in a Chinese study that the most prominent consequence of a change in iodine intake from normal (⬃150 g/d) to moderately high (⬃500 g/d) was a severalfold increase in the prevalence of thyroid hypofunction (29, 30). In our study, new cases of hyper- and hypothyroidism were registered as part of the monitoring of a national iodine supplementation program, before and for 2 yr after iodized salt became available. However, the market share was low, 4468 J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 and the average increase in iodine intake was calculated to be around 5 g/d. The monitoring of two more time periods confirmed the differences between areas observed during the initial study period. In addition, a small but statistically significant increase in the incidence of hyperthyroidism occurred in the area with the lowest iodine intake. Considering the low market share of iodide containing salt, this increase in incidence was unexpected. Further observation will reveal the magnitude and duration of this variation. The study was observational, based on populations with long-term stable iodine intake. It may take years from the time that an increase in iodine intake takes place until a new steady state in occurrence of hyperthyroidism is reached (31, 32). Initially, there may be a transient increase in the incidence of hyperthyroidism (33, 34), which should then fall to a lower level. Little is known about the dynamics of the epidemiology of hypothyroidism after a sudden change in iodine intake. The number of patients diagnosed to have hyper- or hypothyroidism in an area may depend on the diagnostic activity. Individuals of the two population cohorts were not actively investigated for thyroid disease, as they were in the classical Whickham survey (35). In general, the health care system and guidelines for investigation of patients were similar in the two areas. The register accumulated information on the number of thyroid function tests performed in the two cohorts. There were small differences with slightly more TSH analyses performed in Copenhagen and more thyroid hormone tests in Aalborg. This difference could not explain the observed differences in incidence rates of thyroid diseases. Many tests are used for control of disease, and a major reason for the small discrepancy in number of tests between areas may be differences in the abnormalities controlled. New cases identified in the present study had to seek medical assistance, and thyroid tests had to be taken. This might theoretically bias results. However, when we actively examined smaller cohorts from the population of the same areas, the pattern observed was the same (28). In conclusion, small differences in iodine intake of populations with mild and moderate ID are associated with considerable differences in incidence rates of thyroid hyperand hypofunction. The results suggest that small increases in iodine intake of a population with mild and moderate ID will prevent a considerable proportion of nodular hyperthyroidism and goiter. On the other hand, the increase in incidence of thyroid hypofunction observed with an increase in iodine intake may start already below optimal iodine intake levels. The optimal level of iodine intake to prevent thyroid disease may be a relatively narrow range around the recommended daily intake at 150 g. Acknowledgments We are indebted to the GPs in Northern Jutland and Copenhagen and the involved laboratories for their extraordinary spirit of collaboration. Received May 14, 2002. Accepted July 2, 2002. Address all correspondence and requests for reprints to: Inge Bülow Pedersen, Department of Endocrinology and Medicine, Aalborg Hospital, Reberbansgade, DK-9000 Aalborg, Denmark. E-mail: Ibulow@aas. nja.dk. Pedersen et al. • Thyroid Disease and Iodine Intake This study was a part of the Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr), which is supported by grants from the Danish Medical Foundation, the 1991 Pharmacy Foundation, North Jutland County Research Foundation, Tømmerhandler Wilhelm Bangs Foundation, and Copenhagen Hospital Corporation Research Foundation. References 1. WHO-FAO-IAEA 1996 Trace elements in human nutrition and health: iodine. Geneva: World Health Organization; Technical Report 49 2. Hetzel BS, Dunn JT 1989 The iodine deficiency disorders: their nature and prevention. Annu Rev Nutr 9:21–38 3. Delange F 2000 Iodine deficiency. In: Braverman LE, Utiger RD, eds. The thyroid, 8th Ed. Philadelphia: Lippincott; 295–316 4. International Council for the Control of Iodine Deficiency Disorders, Information on iodine supplementation: http://www.iccidd.org (view country information) 5. Pisarev MA, Gärtner R 2000 Autoregulatory actions of iodine. In: Braverman LE, Utiger RD, eds. The thyroid, 8th Ed. Philadelphia: Lippincott; 85–90 6. Tonacchera M, Agretti P, Chiovato L, Rosellini V, Ceccarini G, Perri A, Viacava P, Naccarato AG, Miccoli P, Pinchera A, Vitti P 2000 Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 85:2270 –2274 7. Krohn K, Wohlgemuth S, Gerber H, Paschke R 2000 Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations. J Pathol 192:37– 42 8. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G 1991 High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 229:415– 420 9. Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen P 1998 Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 83:765–769 10. Roti E, Vagenakis AG 2000 Effect of excess iodide: clinical aspects. In: Braverman LE, Utiger RD, eds. The thyroid, 8th Ed. Philadelphia: Lippincott; 316 –329 11. Li M, Liu D, Qu C, Zhang P, Qian Q, Zhang C, Jia Q, Wang H, Eastman CJ, Boyages SC, Collins JK, Jupp JJ, Maberly GF 1987 Endemic goitre in Central China caused by excessive iodine intake. Lancet 1:257–259 12. Konno N, Makita H, Yuri K, Iizuka N, Kawasaki K 1994 Association between dietary iodine intake and prevalence of subclinical hypothyroidism in the coastal regions of Japan. J Clin Endocrinol Metab 78:393–397 13. Suzuki H, Higuchi T, Sawa K, Ohtaki S, Horiuchi Y 1965 “Endemic coast goitre” in Hokkaido, Japan. Acta Endocrinol (Copenh) 50:161–176 14. Safran M, Paul TL, Roti E, Braverman LE 1987 Environmental factors affecting autoimmune thyroid disease. Endocrinol Metab Clin North Am 16:327–342 15. Sundick R, Bagchi N, Brown TR 1992 The role of iodine in thyroid autoimmunity: from chickens to humans. A review. Autoimmunity 13:61– 68 16. Tunbridge WMG, Brewis M, French JM 1981 Natural history of autoimmune thyroiditis. Br Med J 282:258 –262 17. Brown TR, Bagchi N 1992 The role of iodine in the development of autoimmune thyroiditis. Int Rev Immunol 9:167–182 18. Laurberg P, Bülow Pedersen I, Knudsen N, Ovesen L, Andersen S 2001 Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid 11:457– 469 19. Pedersen KM, Nøhr SB, Laurberg P 1997 Iodine intake in Denmark. Ugeskr Læger 159:2201–2206 20. Pedersen KM, Laurberg P, Nøhr S, Jørgensen A, Andersen S 1999 Iodine in drinking water varies by more than 100-fold in Denmark. Importance for iodine content of infant formulas. Eur J Endocrinol 140:400 – 403 21. Rasmussen LB, Ovesen L, Bülow I, Jørgensen T, Knudsen N, Laurberg P, Perrild H 2002 Dietary iodine intake and urinary iodine excretion in a Danish population: effect of geography, supplements and food choice. Br J Nutr 87:61– 69 22. Knudsen N, Bülow I, Jørgensen T, Laurberg P, Ovesen L, Perrild H 2000 Goitre prevalence and thyroid abnormalities at ultrasonography: a comparative epidemiological study in two regions with slightly different iodine status. Clin Endocrinol (Oxf) 53:479 – 485 23. Nøhr SB, Laurberg P, Børlum KG, Pedersen KM, Johannesen PL, Damm P, Fuglsang E, Johansen A 1994 Iodine status in neonates in Denmark: regional variations and dependency on maternal iodine supplementation. Acta Pædiatr 83:578 –582 24. Pedersen KM, Iversen E, Laurberg P 1995 Urinary iodine excretion and individual iodine supplementation among elderly subjects: a cross-sectional investigation in the commune of Randers, Denmark. Eur J Endocrinol 132: 171–174 25. Bülow Pedersen I, Laurberg P, Arnfred T, Knudsen N, Jørgensen T, Perrild H, Ovesen L 2002 Surveillance of disease frequency in a population by linkage Pedersen et al. • Thyroid Disease and Iodine Intake 26. 27. 28. 29. 30. to diagnostic laboratory databases. A system for monitoring the incidences of hyper- and hypothyroidism as part of the Danish iodine supplementation program. Comput Methods Programs Biomed 67:209 –216 Clayton D, Hills M 1993 Statistical models in epidemiology. New York: Oxford University Press; 138 –139 Laurberg P, Nøhr SB, Pedersen KM, Hreidarsson A, Andersen S, Bûlow Pedersen I, Perrild H, Jørgensen T, Ovesen L 2000 Thyroid disorders in mild iodine deficiency. Thyroid 10:951–963 Knudsen N, Bülow I, Jørgensen T, Laurberg P, Ovesen L, Perrild H 2000 Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status. Eur J Endocrinol 143: 485– 491 Shan Z, Teng W, Gao T 2000 The high risk of hypothyroidism in the rural community of China with high iodine intake after universal salt iodination for 3 years. Endocr J 47(Suppl):P-024 Li Y, Teng W, Guan H, Shan Z, Wang Z 2000 The higher prevalence of J Clin Endocrinol Metab, October 2002, 87(10):4462– 4469 4469 31. 32. 33. 34. 35. autoimmune thyroid disease in the rural community with high iodine intake after 3-year universal salt iodination in China. Endocr J 47(Suppl):P-025 Stewart JC, Vidor GI 1976 Thyrotoxicosis induced by iodine contamination of food—a common unrecognised condition? Br Med J 1:372–375 Phillips DI, Barker DJ, Rees Smith B, Didcote S, Morgan D 1985 The geographical distribution of thyrotoxicosis in England according to the presence or absence of TSH-receptor antibodies. Clin Endocrinol (Oxf) 23:283–287 Fradkin J, Wolff J 1983 Iodide-induced thyrotoxicosis. Medicine 62:1–21 Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G 1998 Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8:83–100 Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43:55– 68